- Home
- TCBX vs STOK Comparison
TCBX vs STOK Comparison
Compare TCBX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- STOK
- Stock Information
- Founded
- TCBX 2008
- STOK 2014
- Country
- TCBX United States
- STOK United States
- Employees
- TCBX N/A
- STOK N/A
- Industry
- TCBX Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- STOK Health Care
- Exchange
- TCBX Nasdaq
- STOK Nasdaq
- Market Cap
- TCBX 515.0M
- STOK 556.7M
- IPO Year
- TCBX 2021
- STOK 2019
- Fundamental
- Price
- TCBX $35.51
- STOK $8.33
- Analyst Decision
- TCBX Buy
- STOK Strong Buy
- Analyst Count
- TCBX 4
- STOK 8
- Target Price
- TCBX $37.25
- STOK $23.83
- AVG Volume (30 Days)
- TCBX 81.6K
- STOK 830.1K
- Earning Date
- TCBX 01-22-2025
- STOK 03-24-2025
- Dividend Yield
- TCBX N/A
- STOK N/A
- EPS Growth
- TCBX 40.59
- STOK N/A
- EPS
- TCBX 2.78
- STOK N/A
- Revenue
- TCBX $165,678,000.00
- STOK $16,742,999.00
- Revenue This Year
- TCBX N/A
- STOK $105.42
- Revenue Next Year
- TCBX $6.73
- STOK $15.13
- P/E Ratio
- TCBX $12.76
- STOK N/A
- Revenue Growth
- TCBX 17.16
- STOK 81.08
- 52 Week Low
- TCBX $18.00
- STOK $5.28
- 52 Week High
- TCBX $39.06
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- TCBX 44.85
- STOK 32.00
- Support Level
- TCBX $37.04
- STOK $9.76
- Resistance Level
- TCBX $38.87
- STOK $11.11
- Average True Range (ATR)
- TCBX 1.22
- STOK 0.88
- MACD
- TCBX -0.24
- STOK -0.30
- Stochastic Oscillator
- TCBX 14.72
- STOK 2.31
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company has one segment, community banking, it generates most of its revenue from interest on loans, customer service, and loan fees.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.